SEC Form SCHEDULE 13G filed by Bicycle Therapeutics plc

$BCYC
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $BCYC alert in real time by email





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



 
POINT72 ASSET MANAGEMENT, L.P.
 
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:12/20/2024
 
POINT72 CAPITAL ADVISORS, INC.
 
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:12/20/2024
 
STEVEN A. COHEN
 
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:12/20/2024
Get the next $BCYC alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BCYC

DatePrice TargetRatingAnalyst
11/8/2024$25.00Equal-Weight
Stephens
9/6/2024$35.00Outperform
RBC Capital Mkts
8/7/2024$33.00 → $28.00Buy → Neutral
B. Riley Securities
9/11/2023Neutral → Buy
B. Riley Securities
8/31/2022Outperform
Cowen
7/28/2022$30.00Overweight
Barclays
7/6/2022$60.00Buy
Canaccord Genuity
4/13/2022$62.00 → $33.00Buy → Neutral
B. Riley Securities
More analyst ratings

$BCYC
Press Releases

Fastest customizable press release news feed in the world

See more
  • Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

    Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer; Duravelo-2 dose selection data expected in 2H 2025 Enhanced response to zelenectide pevedotin seen in NECTIN4 gene-amplified late-line breast cancer and non-small cell lung cancer (NSCLC), resulting in U.S. FDA Fast Track designations for triple-negative breast cancer and NSCLC; several Phase 1/2 trials expected to start in 2025 Advancing radiopharmaceuticals pipeline, with additional MT1-MMP human imaging data expected in mid-2025 and first EphA2 human imaging data planned for

    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

    Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, Feb. 12, at 10 a.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the company's website at www.bicycletherapeutics.com. A replay of the webcast will be archived and available following the event. About Bicycle Therapeutics Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of

    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Bicycle Therapeutics plc (NASDAQ:BCYC), today announced that on February 3, 2025, the Compensation Committee of the company's Board of Directors granted to 18 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 117,300 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). Each option has an exercise price equal to $13.39 per share, Bicycle Therapeutics' closing trading price on January 31, 2025, and will vest over four years, wit

    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BCYC
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BCYC
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BCYC
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BCYC
SEC Filings

See more

$BCYC
Leadership Updates

Live Leadership Updates

See more
  • Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

    Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer; Duravelo-2 dose selection data expected in 2H 2025 Enhanced response to zelenectide pevedotin seen in NECTIN4 gene-amplified late-line breast cancer and non-small cell lung cancer (NSCLC), resulting in U.S. FDA Fast Track designations for triple-negative breast cancer and NSCLC; several Phase 1/2 trials expected to start in 2025 Advancing radiopharmaceuticals pipeline, with additional MT1-MMP human imaging data expected in mid-2025 and first EphA2 human imaging data planned for

    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bicycle Therapeutics Expands Clinical Advisory Board with Three Distinguished Global Oncology Experts

    Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointment of three new distinguished global oncology experts to its Clinical Advisory Board (CAB) to support the advancement of the company's clinical oncology programs. "We are delighted to welcome Skip, Markus and Niklas to our Clinical Advisory Board. Each of them has dedicated their careers to advancing the care of patients with cancer through the development of novel therapeutics," said Bicycle Therapeutics CEO Kevin Lee, Ph.D. "Their expertise will provide invaluable guidance

    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Macomics Announces the Appointment of Kevin Lee as Independent Non-Executive Director

    EDINBURGH and CAMBRIDGE, United Kingdom, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has appointed Kevin Lee Ph.D., MBA as Independent Non-Executive Director. Based in the UK and CEO of Cambridge, UK/Cambridge, US based, Bicycle Therapeutics (NASDAQ:BCYC), Kevin brings two decades of biotech and pharma experience to Macomics. In addition to his seat on Bicycle's board of directors, he is also a non-executive director of Alchemab Therapeutics Ltd. Kevin has led Bicycle Therapeutics since 2015, steering it through its strategic growth including various collaborations and financings including through its listing on NAS

    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BCYC
Financials

Live finance-specific insights

See more
  • Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification

    Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025 Heavily pretreated breast cancer and non-small cell lung cancer patients with NECTIN4 gene amplification and/or polysomy demonstrated an enhanced response to zelenectide pevedotin Company to advance development strategy leveraging NECTIN4 gene amplification, with Phase 1/2 trials in breast cancer, lung cancer and multi-tumor planned for 2025 Bicycle Therapeutics to host conference call and webcast with management and

    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update

    Abstract outlines data showing enhanced anti-tumor activity of zelenectide pevedotin monotherapy in triple-negative breast cancer patients with NECTIN4 gene amplification Company to announce topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer and topline monotherapy data for zelenectide pevedotin in non-small cell lung cancer Conference call and webcast scheduled for Friday, Dec. 13, at 7 a.m. CT to review all data Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the

    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Bicycle Therapeutics Announces First Human Imaging Data from European Association of Nuclear Medicine 2024 Congress and Outlines Strategy for Leadership in Next-Generation Radiopharmaceuticals

    First human imaging data validate the potential of MT1-MMP as a novel target in the treatment of cancer and demonstrate positive properties of Bicycle Radionuclide Conjugates (BRC®) for radiopharmaceutical use Additional preclinical data demonstrate biodistribution of BRCs can be optimized to maintain high tumor uptake while significantly reducing kidney levels Company strategy focuses on pursuing novel targets using a range of isotopes to develop radiopharmaceuticals with first-in-class potential Bicycle Therapeutics to host conference call and webcast today at 8 a.m. ET Bicycle Therapeutics plc (NASDAQ:BCYC), a pharmaceutical company pioneering a new and differentiated class of therap

    $BCYC
    Biotechnology: Pharmaceutical Preparations
    Health Care

$BCYC
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more